GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Quality Rank

Adverum Biotechnologies (Adverum Biotechnologies) Quality Rank


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Adverum Biotechnologies Quality Rank Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Executives
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063